No Data
12 Health Care Stocks Moving In Monday's After-Market Session
Dr. Reddy's Laboratories Agreed To Partially Defer A Milestone Payment From Citius Oncology, Inc., Due On September 9, 2024, Upon FDA Approval Of LYMPHIR, Without Penalty, Pending Further Discussions, As Per Their 2021 Asset Purchase Agreement
Express News | Citius Pharmaceuticals Inc - Co Is Guarantor of Obligations of Citius Oncology, Inc Under Asset Purchase Agreement
Express News | Citius Pharmaceuticals - DR. Reddy's Agreed to Partial Deferral Without Penalty of Milestone Payment by Citius Oncology Inc
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Express News | Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Lymphir™ (Denileukin Diftitox-Cxdl) Added to National Comprehensive Cancer Network (Nccn) Clinical Practice Guidelines in Oncology
No Data
No Data